Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria
Authors:
Open Access
- 3 August 2023
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 109 (3) , 929-935
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activityBlood, 2021
- Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuriaHaematologica, 2020
- Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMTFrontiers in Immunology, 2019
- Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to EculizumabClinical Pharmacokinetics, 2019
- Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 studyBlood, 2019
- Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 studyBlood, 2019
- Paroxysmal nocturnal haemoglobinuriaNature Reviews Disease Primers, 2017
- Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activationBlood, 2017
- Measuring the 50% Haemolytic Complement (CH50) Activity of SerumJournal of Visualized Experiments, 2010
- The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaNew England Journal of Medicine, 2006